Brain and Central Nervous System Tumors Clinical Trial
Official title:
A Phase I/II Trial of Temozolomide and ABT-888 in Subjects With Newly Diagnosed Glioblastoma Multiforme
Verified date | June 2018 |
Source | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
RATIONALE: ABT-888 may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in
chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Giving ABT-888 together with
radiation therapy and temozolomide may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of ABT-888 when
given together with radiation therapy and temozolomide and to see how well it works in
treating patients with newly diagnosed glioblastoma multiforme.
Status | Completed |
Enrollment | 24 |
Est. completion date | March 1, 2012 |
Est. primary completion date | March 1, 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 120 Years |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically confirmed supratentorial grade IV astrocytoma (glioblastoma multiforme) - Newly diagnosed disease - Patients enrolled in the phase I initial safety portion of the study must meet the following additional criteria: - Received 90% of planned radiotherapy and = 80% of planned concurrent temozolomide within the past 28-49 days - No grade 3-4 toxicity attributed to temozolomide - Has undergone gadolinium MRI or contrast CT scan within the past 28 days - Patients enrolled in the phase I dose-escalation/phase II portion of the study must meet the following additional criteria: - Recovered from immediate post-operative period and maintained on a stable corticosteroid regimen (no increase in 5 days) prior to starting study treatment - Has undergone gadolinium MRI or contrast CT scan within the past 14 days PATIENT CHARACTERISTICS: - Karnofsky performance status 60-100% - Life expectancy = 3 months - ANC = 1,500/mm^3 - Platelet count = 100,000/mm^3 - Hemoglobin = 9.0 g/dL - Creatinine = 2.0 mg/dL OR creatinine clearance = 60 mL/min - Total bilirubin = 1.5 mg/dL - Transaminases = 2.5 times upper limit of normal - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception prior to, during, and for 3 months after completion of study therapy - Mini Mental State Exam score = 15 - Able to swallow and retain oral medications - No concurrent serious infection or medical illness that would jeopardize the ability of the patient to receive study treatment with reasonable safety - No other malignancy within the past 5 years except for curatively treated carcinoma in situ or basal cell carcinoma of the skin - No known uncontrolled seizure disorder (i.e., status epilepticus) or seizures occurring = 3 times per week over the past month PRIOR CONCURRENT THERAPY: - See Disease Characteristics - More than 10 days since prior cytochrome P450-inducing anticonvulsants (e.g., phenytoin, carbamazepine, phenobarbital, primidone, or oxcarbazepine) - At least 1 week since prior biopsy or resection of tumor (for patients enrolled in the phase I dose-escalation/phase II portion of the study) - No prior radiotherapy, chemotherapy, immunotherapy, hormonal therapy, or biological therapy (including immunotoxins, immunoconjugates, antisense therapy, peptide receptor antagonists, interferons, interleukins, tumor-infiltrating lymphocytes, lymphokine-activated killer cells, or gene therapy) for treatment of brain tumor (for patients enrolled in the phase I dose-escalation/phase II portion of the study) - Prior glucocorticoid therapy allowed - No other prior chemotherapy or investigational agents (for patients enrolled in the phase I initial safety portion of the study) - Prior Gliadel wafers allowed (for patients enrolled in the phase I portion of the study) - No prior Gliadel wafers (for patients enrolled in the phase II portion of the study) |
Country | Name | City | State |
---|---|---|---|
United States | Winship Cancer Institute of Emory University | Atlanta | Georgia |
United States | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore | Maryland |
United States | UAB Comprehensive Cancer Center | Birmingham | Alabama |
United States | Massachusetts General Hospital | Boston | Massachusetts |
United States | Cleveland Clinic Taussig Cancer Center | Cleveland | Ohio |
United States | Josephine Ford Cancer Center at Henry Ford Hospital | Detroit | Michigan |
United States | University of Wisconsin Comprehensive Cancer Center | Madison | Wisconsin |
United States | Abramson Cancer Center of the University of Pennsylvania | Philadelphia | Pennsylvania |
United States | UPMC Cancer Centers | Pittsburgh | Pennsylvania |
United States | UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco | California |
United States | Wake Forest University Comprehensive Cancer Center | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum tolerated dose of ABT-888 (Phase I) | continous | ||
Primary | Overall survival (Phase II) | continous | ||
Secondary | Toxicity (Phase I) | continous | ||
Secondary | Pharmacokinetics of ABT-888 (Phase I) | continous | ||
Secondary | Frequency of toxicity (Phase II) | continous |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00006080 -
Fenretinide in Treating Patients With Recurrent Malignant Glioma
|
Phase 2 | |
Recruiting |
NCT00887146 -
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
|
Phase 3 | |
Suspended |
NCT00935090 -
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
|
N/A | |
Completed |
NCT00621686 -
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT00227032 -
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00112502 -
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT00243022 -
Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme
|
Phase 2 | |
Active, not recruiting |
NCT00087815 -
Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain
|
N/A | |
Active, not recruiting |
NCT00278278 -
Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas
|
Phase 3 | |
Completed |
NCT00416819 -
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
|
N/A | |
Completed |
NCT00052286 -
Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer
|
N/A | |
Completed |
NCT00006093 -
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
|
Phase 1/Phase 2 | |
Recruiting |
NCT00004129 -
Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00004212 -
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT00003417 -
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
Completed |
NCT00003464 -
Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00003020 -
LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases
|
Phase 1 | |
Completed |
NCT00003173 -
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
|
Phase 2 | |
Completed |
NCT00008008 -
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
|
Phase 2 |